US FDA Approves Sanofi’s Rare Disease Drug Xenpozyme
In a campaign to develop the first and best-in-class medicines, Sanofi has gained approval from the US Food and Drug Administration (FDA) for Sanofi’s latest rare disease drug, known as Xenpozyme. In March 2022, the health regulators in Japan signed off on Xenpozyme to treat Niemann-Pick, which is a rare genetic disease that prevents the […]
Continue Reading